Drugs / Herombopag Olamine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06062680 | Oct → Nov 2023 | primary thrombocytopenia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05160857 | Dec 2021 → Dec 2022 | thrombocytopenia | Second Hospital of Shanxi Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Herombopag Olamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05160857 ↗ |
| Route | Oral | “oral on an empty stomach” NCT05160857 ↗ |